Beyond mitigating MASLD progression through the gut–liver axis and alleviating oxidative stress and inflammation via iron chelation, FA also reduces NASH-induced elevations in TC, TG, and LDL levels while suppressing the NF-κB signaling pathway, ultimately ameliorating NASH-mediated liver injury (Figure 5) [126]. Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.